Quinolone antibiotic

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
월요일, 4월 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
월요일, 4월 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Infection, Woman, Allergy, ABSSSI, ATC, Pneumonia, Aztreonam, Skin, International, Nausea, Language, Tissue, DNA, Mouth, Vancomycin, Community-acquired pneumonia, Antimicrobial spectrum, CAP, Quinolone antibiotic, Breastfeeding, European Medicines Agency, Tablet, Select, Patient, Birth, Bacteria, Anatomy, Moxifloxacin, IIA, Meglumine, Medical device

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

New Enhancements and Advancements in the Companion Animal Ear Infection Treatment Market 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
수요일, 8월 23, 2023
Pharmaceutical, Health, Veterinary, Cats and Dogs, Pressure, High, Research report, Block cipher mode of operation, Labyrinthitis, Dog, COVID-19, Consumer, Research, USD, Cat, Certification, Compound annual growth rate, Otitis externa, Social impact assessment, Investment, Quinolone antibiotic, Oral, R, Vaccine, Pharmaceutical industry, Pet industry, Topical medication, Aminoglycoside, Otitis media

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.

Key Points: 
  • The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Companion Animal Ear Infection Treatment Market?
  • What is the market share of the leading vendors in the Global Companion Animal Ear Infection Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Companion Animal Ear Infection Treatment Market?

Recce Pharmaceuticals Announces RECCE® Trademark Registered in Hong Kong, Strengthening Global IP Portfolio

Retrieved on: 
금요일, 2월 3, 2023
ASX, FSE, Hospital, IP, MRSA, Gram-negative bacteria, RCE, Hospital Authority, Methicillin-resistant Staphylococcus aureus, Quinolone antibiotic, Pharmaceutical industry

This newly registered trademark strengthens the Company’s global intellectual property (IP) portfolio.

Key Points: 
  • This newly registered trademark strengthens the Company’s global intellectual property (IP) portfolio.
  • The Company has been issued Hong Kong Trademark No.
  • 306020153 and has been classified under Class 5 for antibiotics, antibiotics for human use and pharmaceutical preparations, namely mixed antibiotic preparations.
  • “With patents in Hong Kong for RECCE® anti-infectives in place out to 2037, we now celebrate further exclusivity through the trademark registration of RECCE®,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Animal Antibiotics and Antimicrobials Global Market to Reach $5.26 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
수요일, 9월 14, 2022
Pharmaceutical, Agriculture, Health, Natural Resources, Mode, Milk, Human, Diet, Asia-Pacific, Poultry, Meat, Acquisition, Bayer, Growth, Partnership, Industry, Egg, Tetracycline antibiotics, Solution, ADM, Research, PETS, Animal, Livestock, Aquaculture, Animal husbandry, Sulfonamide, Cephalosporin, Aminoglycoside, Elanco, Lincosamides, Macrolide, Penicillin, Injection, Quinolone antibiotic

The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the animal antibiotics and antimicrobials market in 2021.
  • The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market.

Author of Perilous Pills Warns Public About Fluoroquinolone Antibiotic Harm

Retrieved on: 
수요일, 6월 16, 2021
Drugs, Chemical compounds, Fluoroquinolone antibiotics, Health care, Quinolone antibiotic, Levofloxacin, Moxifloxacin, Ciprofloxacin, Ofloxacin, Antibiotic, Heise, Opioid

EAST BOOTHBAY, Maine, June 16, 2021 /PRNewswire/ -- Marilyn Beardsley Heise discovered that opioids aren't the only dangerous drugs after she took a commonly-prescribed fluoroquinolone antibiotic called Levaquin and developed severe tendinitis.

Key Points: 
  • EAST BOOTHBAY, Maine, June 16, 2021 /PRNewswire/ -- Marilyn Beardsley Heise discovered that opioids aren't the only dangerous drugs after she took a commonly-prescribed fluoroquinolone antibiotic called Levaquin and developed severe tendinitis.
  • Heise started investigating and discovered hundreds of thousands had been harmed by these drugs, which include Cipro and Avelox.
  • Extensive research resulted in a book called Perilous Pills, Protecting Yourself from Fluoroquinolone Injury .
  • Much more attention and research are needed, according to the author.

MerLion Pharmaceuticals Completes Growth Financing Round

Retrieved on: 
화요일, 5월 18, 2021
Fluoroquinolone antibiotics, Chemical compounds, Drugs, Chemistry, Cyclopropanes, Finafloxacin, Nitriles, Otologicals, Ofloxacin, Quinolone antibiotic, Otitis externa, Merlion

\xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.

Key Points: 
  • \xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.
  • Its superior, fast acting properties will aid patients considerably in their recovery.\xe2\x80\x9d\nMerLion Pharmaceuticals GmbH is a is a privately held company biopharmaceutical company headquartered in Berlin, Germany.
  • MerLion is supported by a group of leading global investors.
  • For more information, please visit http://www.merlionpharma.com\nPOELLATH, Munich, Dr. Michael Inhester and Adalbert Makos advised MerLion on the investment and capital raise.\nFinafloxacin is a novel fluoroquinolone antibiotic with best-in-class features.

New Report by World Animal Protection Documents Antibiotic Resistance in the Environment Near US Factory Farms

Retrieved on: 
월요일, 4월 19, 2021
Articles, Health sciences, Health, Fluoroquinolone antibiotics, Livestock, Meat industry, Evolutionary biology, Pharmaceuticals policy, Ofloxacin, Quinolone antibiotic, Cephalosporin, Intensive animal farming

However, the high density of pig and poultry farms in the area means that upstream sample sites may be regularly impacted by discharges from farms further upstream.\n"The implications of antibiotic resistance throughout the environment near large factory farms are extremely concerning," says Cameron Harsh, Farming Campaign Manager, World Animal Protection US.

Key Points: 
  • However, the high density of pig and poultry farms in the area means that upstream sample sites may be regularly impacted by discharges from farms further upstream.\n"The implications of antibiotic resistance throughout the environment near large factory farms are extremely concerning," says Cameron Harsh, Farming Campaign Manager, World Animal Protection US.
  • "\nThe new report reveals very wide evidence of ARGs conveying resistance to streptomycin, fluoroquinolones, cephalosporins, macrolides, and mostbroadly, tetracycline.
  • Their prevalence near swine farms has been previously reported, and the World Health Organization (WHO) identifies them as a global threat.
  • ARGs conveying resistance to important medicines were identified in all countries, including resistance to cephalosporins and fluoroquinolones.

Animal Antibiotics and Antimicrobials Market worth $5.6 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
월요일, 3월 8, 2021
Health sciences, Health, Articles, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine, Fluoroquinolone antibiotics, Quinolone antibiotic, Antimicrobial, Antibiotic, Ofloxacin, Sulfonamide

Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.

Key Points: 
  • Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.
  • In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antibiotics market.
  • Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals.
  • The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.